GNTA · Genenta Science S.p.A.
$1.49
-0.08 (-5.10%)
At close · Jul 29
Market Cap
$75.70M
Shares
48.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.57
Open$1.53
Day$1.45–1.60
52W$0.56–10.00
Avg vol 30d173K
Short int146K · 0.3% float · 1.5d
Short vol32%
DataDec 2021–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
+4%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
11%
near low
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+78%
trailing
YTD return
+5%
this year
Relative strength
+70%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Distributing
2 of 11 funds reported for Jun 30 · net -4.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.30% of float · ▼ -12.3% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
11 holders — mid 3-yr range
Squeeze score
36
low risk · 0–100
Fundamentals
EPS growth
+33%
Y/Y
Balance sheet
$25.7M
net cash
Quant / Vol
risk profile
Volatility
161%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
9.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
Golden cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Distributing
2 of 11 funds reported for Jun 30 · net -4.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.30% of float · ▼ -12.3% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
11 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 11%
52-wk high $10
vs 200-day avg +8%
vs 50-day avg +4%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GNTA
this stock
Genenta Science S.p.A.
|
$75.70M | +5.4% | — | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$473.24B | +7.3% | +22179.2% | 963.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
11
- % held
- 2.1%
- Reported
- 2 of 11
- Top holder
- Eurizon Capital SGR S.p.A.
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GNTA | -4.9% | -12.8% | +77.6% | -14.7% | +5.4% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -3.9% | -12.8% | +70.2% | -13.9% | -3.3% |